Anthos Therapeutics is focused on developing innovative anticoagulant therapies, particularly through their investigational agent, abelacimab. This novel anticoagulant targets Factor XI, a protein involved in the coagulation cascade, and has shown promising results in clinical trials. The AZALEA-TIMI 71 study demonstrated that abelacimab significantly reduces the risk of major bleeding events compared to standard anticoagulants like rivaroxaban, with a reported 67% reduction in major or clinically relevant non-major bleeding. Additionally, abelacimab has been associated with a remarkable 80% reduction in venous thromboembolism (VTE) rates following surgical procedures, indicating its potential as a safer alternative for patients at risk of thrombotic events.

The company is also addressing unmet medical needs in various patient populations, including those with atrial fibrillation and cancer-associated thrombosis. The ongoing clinical development programs, such as the LILAC-TIMI 76 and the Cancer Associated Thrombosis (CAT) program, aim to evaluate the efficacy and safety of abelacimab in diverse settings. These studies are designed to enroll thousands of patients globally, further establishing abelacimab's role in preventing strokes and managing thrombosis in patients who may be unsuitable for existing anticoagulant therapies. With FDA Fast-Track designations for both stroke prevention and cancer-associated thrombosis, Anthos Therapeutics is positioned to make significant advancements in anticoagulant therapy.

United States

Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases.

Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019. 

Anthos Therapeutics

Company Details